Trastuzumab subcutaneous

Drug Profile

Trastuzumab subcutaneous

Alternative Names: Herceptin SC; Hyaluronidase-trastuzumab; Reformulated Herceptin - Halozyme/Roche; RG597 (SC formulation) - Roche/Halozyme; Trastuzumab SC; Trastuzumab-hyaluronidase

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 07 Oct 2016 Pooled safety results from the phase III trials in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Oct 2016 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Oct 2016 Adverse events data from a phase III trial in Breast cancer presented at 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top